Brief: Bio-Path Provides Key Clinical Updates
13/02/2025 13:05
Feb 13 (Reuters) - Bio Path Holdings BPTH.O :
* BIO-PATH HOLDINGS PROVIDES KEY CLINICAL UPDATES
* BIO PATH HOLDINGS: REPORTS CONTINUED PATIENT PROGRESS FROM
PHASE
2 TRIPLE COMBINATION STUDY OF PREXIGEBERSEN IN ACUTE MYELOID
LEUKEMIA (AML)
Source text: ID:nGNX3SPmN1
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia